

Resource Summary Report

Generated by RRID on Aug 7, 2026

CD133/1 Antibody, anti-human, PE-Vio® 770

RRID:AB_2725939

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-110, RRID:AB_2725939

Antibody Information

URL: http://antibodyregistry.org/AB_2725939

Proper Citation: Miltenyi Biotec Cat# 130-113-110, RRID:AB_2725939

Target Antigen: CD133/1

Host Organism: mouse

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-101-676. (RRID:AB_2660887).

Antibody Name: CD133/1 Antibody, anti-human, PE-Vio® 770

Description: This monoclonal targets CD133/1

Target Organism: human

Clone ID: clone AC133

Antibody ID: AB_2725939

Vendor: Miltenyi Biotec

Catalog Number: 130-113-110

Record Creation Time: 20250820T002839+0000

Record Last Update: 20250820T082215+0000

Ratings and Alerts

No rating or validation information has been found for CD133/1 Antibody, anti-human, PE-Vio® 770.

No alerts have been found for CD133/1 Antibody, anti-human, PE-Vio® 770.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Della Volpe L, et al. (2025) Protocol for optimizing culture conditions for ex vivo activation during CRISPR-Cas9 gene editing in human hematopoietic stem and progenitor cells. STAR protocols, 6(2), 103722.

Conti A, et al. (2025) Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells. Cell reports. Medicine, 6(6), 102157.

Della Volpe L, et al. (2024) A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells. Cell reports. Medicine, 5(11), 101823.